Last 7 days
-3.4%
Last 30 days
2.1%
Last 90 days
14.8%
Trailing 12 Months
22.4%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
BGNE | 322.8B | 1.6B | -3.71% | 80.48% | -168.39 | 207.32 | 77.54% | 1.62% |
ABBV | 285.4B | 56.7B | -14.98% | -6.85% | 24.12 | 4.92 | 0.03% | -39.22% |
REGN | 87.6B | 12.4B | -6.81% | 6.09% | 20.2 | 7.2 | -25.07% | -47.28% |
VRTX | 85.0B | 9.2B | 2.07% | 22.38% | 26.07 | 9.23 | 15.86% | 32.99% |
ALNY | 23.4B | 1.0B | -4.69% | 49.89% | -21.96 | 22.55 | 22.88% | -19.27% |
SRPT | 11.8B | 975.7M | 3.71% | 78.87% | -10.59 | 12.11 | 27.41% | -212.78% |
UTHR | 9.7B | 2.0B | -8.21% | -7.77% | 13.31 | 4.89 | 12.05% | 52.86% |
MID-CAP | ||||||||
MDGL | 5.2B | 504.0K | -7.29% | 316.43% | -16.55 | 2.5K | -66.53% | -27.52% |
RARE | 3.5B | 363.3M | 17.72% | 8.70% | -4.94 | 9.63 | 3.39% | -55.81% |
BPMC | 3.5B | 204.6M | 17.81% | 4.32% | -6 | 17.05 | -7.52% | 10.65% |
MRTX | 2.2B | 18.9M | -10.74% | -34.21% | -3.03 | 118.36 | - | -16.17% |
SMALL-CAP | ||||||||
CYTK | 3.5B | - | 0.59% | -4.18% | -8.22 | 37.46 | 34.30% | -67.22% |
CPRX | 1.2B | 256.5M | -28.21% | 63.82% | 12.26 | 4.75 | 66.85% | 120.61% |
MGNX | 315.4M | 165.3M | -25.22% | 48.69% | -3.45 | 1.91 | 130.70% | 57.97% |
CRBP | 41.8M | 881.7K | 29.00% | 3203.36% | -0.83 | 19.11 | -77.61% | -29.84% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Revenue | 3.1% | 9,208 | 8,931 | 8,701 | 8,350 | 7,948 |
S&GA Expenses | 2.7% | 971 | 945 | 933 | 884 | 863 |
R&D Expenses | - | 3,198 | - | - | - | - |
Costs and Expenses | 11.7% | 5,163 | 4,623 | 4,549 | 4,271 | 5,012 |
EBITDA | 5.2% | 4,326 | 4,112 | 4,012 | 2,936 | - |
EBITDA Margin | 2.5% | 0.48* | 0.47* | 0.48* | 0.37* | - |
Earnings Before Taxes | -1.5% | 4,169 | 4,232 | 4,027 | 3,933 | 2,864 |
EBT Margin | 2.4% | 0.47* | 0.46* | 0.47* | 0.36* | - |
Interest Expenses | 6.0% | -54.80 | -58.30 | -59.80 | -60.70 | - |
Net Income | -1.9% | 3,260 | 3,322 | 3,273 | 3,195 | 2,451 |
Net Income Margin | -1.1% | 0.37* | 0.38* | 0.38* | 0.31* | - |
Free Cahsflow | 2.9% | 3,925 | 3,814 | 3,787 | 2,451 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Assets | 4.5% | 18,974 | 18,151 | 16,706 | 15,582 | 14,256 |
Current Assets | -2.0% | 12,966 | 13,235 | 12,271 | 11,504 | 10,361 |
Cash Equivalents | -11.6% | 9,290 | 10,504 | 9,172 | 8,702 | 7,600 |
Inventory | 16.2% | 535 | 461 | 388 | 368 | 339 |
Goodwill | -1.1% | 1,088 | 1,100 | 86.00 | 1,002 | 1,002 |
Liabilities | 7.2% | 4,542 | 4,238 | 3,677 | 3,649 | 3,349 |
Current Liabilities | 10.4% | 3,026 | 2,742 | 2,609 | 2,556 | 2,180 |
Shareholder's Equity | 3.7% | 14,432 | 13,913 | 13,030 | 11,934 | 10,907 |
Retained Earnings | 10.7% | 7,223 | 6,523 | 5,704 | 4,773 | 3,963 |
Additional Paid-In Capital | -2.3% | 7,220 | 7,387 | 7,226 | 7,100 | 6,930 |
Shares Outstanding | 0.2% | 258 | 257 | 257 | 256 | 256 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Cashflow From Operations | -1.4% | 4,074 | 4,130 | 4,047 | 4,018 | 2,679 |
Share Based Compensation | -1.6% | 483 | 491 | 498 | 466 | 457 |
Cashflow From Investing | -555.2% | -2,103 | -321 | -630 | -299 | -317 |
Cashflow From Financing | -294.4% | -267 | -67.70 | -444 | -1,040 | -1,054 |
Buy Backs | Infinity% | 133 | 0.00 | 368 | 1,010 | 1,010 |
25.8%
6.5%
0%
Y-axis is the maximum loss one would have experienced if Vertex Pharmaceuticals was unfortunately bought at previous high price.
15.5%
20.3%
15.9%
7.4%
FIve years rolling returns for Vertex Pharmaceuticals.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-05-24 | Old North State Trust, LLC | unchanged | - | 3,000 | 32,000 | 0.02% |
2023-05-23 | Toroso Investments, LLC | added | 43.09 | 3,909,000 | 10,878,000 | 0.19% |
2023-05-23 | Seaport Global Advisors, LLC | reduced | -34.06 | -138,205 | 354,454 | 1.12% |
2023-05-23 | Brookfield Corp /ON/ | new | - | 366,426 | 366,426 | -% |
2023-05-23 | 3Chopt Investment Partners, LLC | new | - | 1,920,350 | 1,920,350 | 1.02% |
2023-05-22 | AMERIPRISE FINANCIAL INC | reduced | -5.28 | 34,587,100 | 1,068,030,000 | 0.35% |
2023-05-22 | PUTNAM INVESTMENTS LLC | reduced | -11.22 | -1,213,060 | 37,475,400 | 0.06% |
2023-05-22 | Raleigh Capital Management Inc. | new | - | 5,986 | 5,986 | -% |
2023-05-22 | Arete Wealth Advisors, LLC | new | - | 236,000 | 236,000 | 0.02% |
2023-05-22 | FDx Advisors, Inc. | unchanged | - | - | 2,075,000 | 0.09% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 13, 2023 | capital world investors | 5.0% | 12,939,319 | SC 13G | |
Feb 09, 2023 | vanguard group inc | 8.39% | 21,546,903 | SC 13G/A | |
Feb 09, 2023 | fmr llc | - | 0 | SC 13G | |
Jan 24, 2023 | blackrock inc. | 9.4% | 24,241,437 | SC 13G | |
Feb 14, 2022 | price t rowe associates inc /md/ | 2.1% | 5,421,291 | SC 13G/A | |
Feb 10, 2022 | vanguard group inc | 7.93% | 20,155,842 | SC 13G/A | |
Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
Feb 01, 2022 | blackrock inc. | 9.4% | 23,944,931 | SC 13G/A | |
Feb 16, 2021 | price t rowe associates inc /md/ | 7.5% | 19,626,208 | SC 13G/A | |
Feb 10, 2021 | vanguard group inc | 7.86% | 20,433,050 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
May 18, 2023 | 8-K | Current Report | |
May 09, 2023 | 4 | Insider Trading | |
May 09, 2023 | 4 | Insider Trading | |
May 08, 2023 | 144 | Notice of Insider Sale Intent | |
May 08, 2023 | 144 | Notice of Insider Sale Intent | |
May 05, 2023 | 144 | Notice of Insider Sale Intent | |
May 05, 2023 | 144 | Notice of Insider Sale Intent | |
May 04, 2023 | 4 | Insider Trading | |
May 04, 2023 | 4 | Insider Trading | |
May 03, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-05-08 | Sanna Bastiano | sold | -997,500 | 350 | -2,850 | evp, cell & genetic therapies |
2023-05-08 | LEIDEN JEFFREY M | sold | -392,625 | 349 | -1,125 | executive chairman |
2023-05-05 | LEIDEN JEFFREY M | sold | -307,262 | 349 | -879 | executive chairman |
2023-05-05 | Sanna Bastiano | sold | -147,713 | 350 | -422 | evp, cell & genetic therapies |
2023-05-03 | Sanna Bastiano | sold | -975,418 | 350 | -2,781 | evp, cell & genetic therapies |
2023-05-03 | LEIDEN JEFFREY M | sold | -1,578,300 | 350 | -4,508 | executive chairman |
2023-05-02 | Sanna Bastiano | sold | -568,768 | 350 | -1,622 | evp, cell & genetic therapies |
2023-05-02 | Bhatia Sangeeta N. | sold | -202,004 | 348 | -580 | - |
2023-05-02 | LEIDEN JEFFREY M | sold | -2,256,760 | 349 | -6,450 | executive chairman |
2023-05-01 | MCKENZIE DIANA | acquired | - | - | 1,168 | - |
Condensed Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions | 3 Months Ended | |
---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
Revenues: | ||
Product revenues, net | $ 2,374.8 | $ 2,097.5 |
Costs and expenses: | ||
Cost of sales | 266.9 | 245.8 |
Research and development expenses | 742.6 | 601.1 |
Acquired in-process research and development expenses | 347.1 | 2.0 |
Selling, general and administrative expenses | 241.1 | 215.2 |
Change in fair value of contingent consideration | (1.9) | (7.5) |
Total costs and expenses | 1,595.8 | 1,056.6 |
Income from operations | 779.0 | 1,040.9 |
Interest income | 122.6 | 1.6 |
Interest expense | (11.4) | (14.9) |
Other income (expense), net | 1.3 | (72.8) |
Income before provision for income taxes | 891.5 | 954.8 |
Provision for income taxes | 191.7 | 192.7 |
Net income | $ 699.8 | $ 762.1 |
Net income per common share: | ||
Basic (in dollars per share) | $ 2.72 | $ 2.99 |
Diluted (in dollars per share) | $ 2.69 | $ 2.96 |
Shares used in per share calculations: | ||
Basic (in shares) | 257.4 | 255.1 |
Diluted (in shares) | 260.3 | 257.9 |
Condensed Consolidated Balance Sheets - USD ($) $ in Millions | Mar. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 9,289.9 | $ 10,504.0 |
Marketable securities | 1,124.2 | 274.5 |
Accounts receivable, net | 1,547.8 | 1,442.2 |
Inventories | 535.1 | 460.6 |
Prepaid expenses and other current assets | 468.7 | 553.5 |
Total current assets | 12,965.7 | 13,234.8 |
Property and equipment, net | 1,111.7 | 1,108.4 |
Goodwill | 1,088.0 | 1,088.0 |
Intangible assets | 603.6 | 603.6 |
Deferred tax assets | 1,359.9 | 1,246.9 |
Operating lease assets | 336.3 | 347.4 |
Long-term marketable securities | 1,081.5 | 112.2 |
Other assets | 427.5 | 409.6 |
Total assets | 18,974.2 | 18,150.9 |
Current liabilities: | ||
Accounts payable | 323.2 | 303.9 |
Accrued expenses | 2,326.0 | 2,126.7 |
Other current liabilities | 377.0 | 311.5 |
Total current liabilities | 3,026.2 | 2,742.1 |
Long-term finance lease liabilities | 417.6 | 430.8 |
Long-term operating lease liabilities | 371.6 | 379.5 |
Other long-term liabilities | 726.5 | 685.8 |
Total liabilities | 4,541.9 | 4,238.2 |
Commitments and contingencies | 0.0 | 0.0 |
Shareholders’ equity: | ||
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding | 0.0 | 0.0 |
Common stock, $0.01 par value; 500,000,000 shares authorized, 257,509,761 and 257,011,628 shares issued and outstanding, respectively | 2.6 | 2.6 |
Additional paid-in capital | 7,220.2 | 7,386.5 |
Accumulated other comprehensive (loss) income | (13.1) | 0.8 |
Retained earnings | 7,222.6 | 6,522.8 |
Total shareholders’ equity | 14,432.3 | 13,912.7 |
Total liabilities and shareholders’ equity | $ 18,974.2 | $ 18,150.9 |